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Abstract Angiostatin is a potent angiogenic inhibitor. The
present study identi¢ed a new activity of angiostatin: reducing
vascular leakage, which is associated with diabetic macular ede-
ma, tumor growth and in£ammation. An intravitreal injection of
angiostatin signi¢cantly reduced retinal vascular permeability in
rats with oxygen-induced retinopathy and in those with strepto-
zotocin-induced diabetes, but not in normal rats. Consistent with
its e¡ect on permeability, angiostatin downregulated vascular
endothelial growth factor (VEGF) expression in the retina in
both the rat models but not in normal controls. These results
suggest that the e¡ect of angiostatin on vascular leakage is
mediated, at least in part, through blockade of VEGF overex-
pression.
* 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Angiostatin is a proteolytic fragment (kringle 1^4) of plas-
minogen [1]. It was identi¢ed as a potent angiogenic inhibitor
which blocks neovascularization and suppresses tumor growth
and metastases [1]. Angiostatin speci¢cally inhibits prolifera-
tion and induces apoptosis in vascular endothelial cells [2].
Recent evidence has suggested that decreased angiostatin lev-
els in the vitreous may play a role in the development of
proliferative diabetic retinopathy [3]. Moreover, recombinant
angiostatin has been shown to block retinal neovasculariza-
tion in a rat model of oxygen-induced retinopathy (OIR) [4].
Delivery of a recombinant virus expressing angiostatin has
been found to suppress laser-induced choroidal neovasculari-
zation [5]. These ¢ndings reveal therapeutic potential of an-
giostatin in the treatment of retinal neovascularization as well
as in the treatment of cancer.
The blood-retinal barrier (BRB) breakdown, increased vas-
cular permeability or vascular leakage is an early complication
of diabetes and a major cause of diabetic macular edema [6,7].
At early stages of diabetic retinopathy, it is found that the
increase of retinal vascular permeability precedes the appear-
ance of clinical retinopathy [6,7]. As there is no satisfactory,
non-invasive therapy, diabetic macular edema is a major cause
of vision loss in diabetic patients [8]. Although the pathogenic
mechanism underlying the breakdown of the BRB and the
increase of retinal vascular permeability is uncertain, the over-
production of vascular endothelial growth factor (VEGF) in
the retina is believed to play a key role in the development of
vascular hyperpermeability in diabetes [9,10].
In this study, we have determined the e¡ect of angiostatin
on vascular permeability in OIR and streptozotocin (STZ)-
induced diabetic models and studied its possible mechanism.
2. Materials and methods
2.1. Animals
Brown Norway rats were purchased from Harlan (Indianapolis, IN,
USA). Care, use, and treatment of all animals in this study were in
strict agreement with the ARVO statement for the Use of Animals in
Ophthalmic and Vision Research.
2.2. Rat models of OIR and diabetes
OIR was induced by exposing newborn rats to 75% O2 as described
by Smith et al. [11] with some modi¢cations [12]. Diabetes was in-
duced in adult rats (8 weeks of age) by an intravenous injection of
STZ (50 mg/kg) after overnight fasting. Rats with glucose levels high-
er than 350 mg/dl were considered diabetic.
2.3. Intravitreal injection of angiostatin
Angiostatin (Angiogenesis Research Industries, Inc., Chicago, IL,
USA) was reconstituted in sterile phosphate-bu¡ered saline (PBS) and
injected into the vitreous of the right eye (3 Wl/eye) of the anesthetized
rats through the pars plana using a glass capillary. The left eye re-
ceived the same volume of sterile PBS as the control.
2.4. Measurement of vascular permeability
Vascular permeability was quanti¢ed by measuring albumin leakage
from blood vessels into the retina and iris using the Evans blue meth-
od following a documented protocol [13] with minor modi¢cations
[14].
2.5. Western blot analysis and immunohistochemistry of VEGF
VEGF Western blot analysis was performed using an antibody
speci¢c for VEGF (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA) as described previously [15]. Immunohistochemistry was
carried out following a documented protocol [16].
2.6. Statistical analysis
Statistical analysis employed Student’s t-test. The paired t-test was
used for comparison of the angiostatin-injected eye with the PBS-
injected contralateral controls from the same animal, while the un-
paired test was used for interanimal comparison.
0014-5793 / 04 / $30.00 K 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/S0014-5793(04)00297-2
*Corresponding author. Fax: (1)-405-271 3973.
E-mail address: jian-xing-ma@ouhsc.edu (J.-x. Ma).
Abbreviations: BRB, blood-retinal barrier; OIR, oxygen-induced ret-
inopathy; STZ, streptozotocin; VEGF, vascular endothelial growth
factor
FEBS 28252 7-4-04 Cyaan Magenta Geel Zwart
FEBS 28252 FEBS Letters 564 (2004) 19^23
3. Results
3.1. Angiostatin reduces vascular permeability in the retina of
OIR rats
Previous studies showed that OIR rats have a transient
increase of retinal vascular permeability with the peak at
age P16 [17]. To determine the e¡ect of angiostatin on vascu-
lar permeability, OIR rats (P14) received an intravitreal injec-
tion of 3 Wl of angiostatin with di¡erent concentrations into
the right eyes, to reach doses of 1.875, 3.75 and 7.5 Wg/eye,
and the same volume of PBS into the left eyes for controls.
Fig. 1. Angiostatin dose-dependent reduction of vascular permeabil-
ity in OIR rat retina. Rats received an intravitreal injection of an-
giostatin in the right eye and PBS in the left eye at age P14. Retinal
vascular permeability was measured at P16 using the Evans blue
method and normalized by total protein concentrations in the reti-
na. Permeability was expressed as percentage of the contralateral
control (meanOS.D., n=4). 1, age-matched normal rats with a PBS
injection; 2, OIR rats with a PBS injection; 3, 4 and 5, OIR rats
with an injection of 1.875, 3.75 and 7.5 Wg/eye of angiostatin, re-
spectively.
Fig. 2. Time course of the angiostatin-induced reduction of vascular
permeability. At age P14, the right eye of the OIR rats received an
intravitreal injection of angiostatin (7.5 Wg/eye) and the left eye re-
ceived PBS as the control. Vascular permeability was measured at 1,
2 and 3 days after the injection. Vascular permeability was normal-
ized by the total protein concentrations in the retina and expressed
as percentage of the contralateral control (meanOS.D., n=4). ns.,
not statistically signi¢cant.
Fig. 3. Angiostatin-induced reduction of vascular permeability in STZ-diabetic rats. Angiostatin was injected into the vitreous of the right eye
(7.5 Wg/eye) and PBS into the left eye of the STZ-diabetic rats (A, B) and normal adult rats (C, D). Vascular permeability in the retina and iris
was measured 2 days after the injection, normalized by total protein concentrations in the tissues and expressed as percentage of the contralat-
eral control (meanOS.D., n=4). A, B: Angiostatin reduced vascular permeability in the retina and iris of STZ-diabetic rats. C, D: Angiostatin
does not a¡ect vascular permeability in normal rats. PBS, PBS-injected eye; Ang, angiostatin-injected eye.
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Vascular permeability was measured at P16 using the Evans
blue method. In the eyes injected with angiostatin, vascular
permeability was reduced in an angiostatin dose-dependent
manner (Fig. 1). At doses of 3.75 and 7.5 Wg/eye, angiostatin
decreased the permeability to approximately 70 and 50%, re-
spectively, of the contralateral control with PBS injection
(P6 0.05 and P6 0.01, respectively, n=4), while the low
dose of angiostatin (1.875 Wg/eye) showed no signi¢cant re-
duction in permeability (Ps 0.05, n=4) (Fig. 1). No signi¢-
cant reduction of vascular permeability was detected in the iris
of OIR rats treated with angiostatin of all the doses used
(data not shown).
To determine the e¡ect of angiostatin on retinal neovascu-
larization, angiostatin was injected into the vitreous of the
right eye (7.5 Wg/eye) of OIR rats at P12 and PBS into the
left eye. The retinal neovascularization was examined at P18
using both the £uorescein angiography on retinal whole
mounts and by quantifying pre-retinal vascular cells as de-
scribed previously [11]. Both results showed that angiostatin,
at the dose used, had no detectable e¡ect on retinal neovas-
cularization at this early time point (data not shown), sug-
gesting that the angiostatin-induced reduction of vascular
permeability is not a consequence of inhibition of retinal neo-
vascularization.
3.2. Time course of the angiostatin-induced reduction of
vascular permeability in OIR rat retina
OIR rats received an intravitreal injection of 7.5 Wg/eye of
angiostatin at P14 in the right eye and PBS in the left eye.
Vascular permeability was measured at P15, P16 and P17.
Angiostatin injection reduced retinal vascular permeability
to approximately 70 and 50% of the contralateral control
(P6 0.05 and P6 0.01, respectively, n=4) at P15 and P16,
respectively (Fig. 2). At P17, 3 days after the injection, vas-
cular permeability returned to the level of the PBS-injected
contralateral control. No signi¢cant reduction of vascular per-
meability was observed in the iris at these time points (data
not shown).
3.3. E¡ect of angiostatin on retinal vascular leakage in diabetic
rats
The STZ-diabetic rats received an intravitreal injection of
angiostatin (7.5 Wg/eye) in the right eye and PBS in the left eye
at 2 weeks following the onset of diabetes. Vascular perme-
ability in the retina and iris was measured 2 days after the
injection. Angiostatin signi¢cantly decreased vascular perme-
ability to 30% of the control with PBS injection (P6 0.01,
n=4) in the retina and to 70% of the control in the iris
(P6 0.05, n=4) (Fig. 3A and B).
In contrast, intravitreal injection of the same dose of an-
giostatin did not result in any signi¢cant reduction of vascular
permeability in the retina and iris of normal rats, when com-
pared with the contralateral eye with PBS injection (Ps 0.05,
n=4) (Fig. 3C and D).
3.4. Angiostatin downregulates VEGF expression in the retina
of the STZ-diabetic and OIR rats but not in normal rats
As overexpression of VEGF is known as a major cause of
vascular hyperpermeability, we have determined the e¡ect of
angiostatin on VEGF expression in OIR, STZ-diabetic and
normal rats. Angiostatin was injected into the vitreous of
the right eyes (7.5 Wg/eye) and PBS into the left eyes of OIR
rats at age P14, or into STZ-diabetic rats at 2 weeks after the
onset of diabetes and age-matched normal adult rats. 1 day
Fig. 4. Angiostatin-mediated downregulation of VEGF expression in the retinas. OIR rats (P14), STZ-diabetic rats (2 weeks of diabetes) and
normal adult rats received an intravitreal injection of angiostatin (7.5 Wg/eye) in the right eye and PBS in the left eye. Retinal VEGF levels
were determined by Western blot analysis using an anti-VEGF antibody 1 day after the injection. The same membranes were striped and re-
blotted with the anti-L-actin antibody (upper panels). Each blot is a representative of results from three rats in each group. VEGF levels were
semiquanti¢ed by densitometry, normalized by L-actin levels and expressed as percentage of control (lower panels). PBS, PBS-injected eye;
Ang, angiostatin-injected eye; ns., not statistically signi¢cant.
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following the injection, VEGF levels in the retina were mea-
sured by Western blot analysis using an antibody speci¢c for
VEGF. Angiostatin decreased VEGF levels by approximately
2.5- and 2-fold in the retinas of the OIR and STZ-diabetic
rats, respectively, but not in normal rats (Fig. 4), correlating
with its e¡ect on vascular permeability.
Immunohistochemistry using the anti-VEGF antibody dem-
onstrated that angiostatin decreased the intensity of VEGF
signals in the retina of the OIR rats, 1 day following the
injection, when compared to the PBS-injected contralateral
eye (Fig. 5).
4. Discussion
Angiostatin has been shown to inhibit endothelial cells [1].
In the present study, we identi¢ed a new activity of angiosta-
tin, i.e. reducing pathological vascular permeability in the ret-
inas of both OIR and STZ-diabetic rat models but not in
normal rats. Further, our results for the ¢rst time showed
that angiostatin downregulates VEGF expression in the reti-
nas of both the OIR and STZ diabetes models, but not in
normal rat retina, correlating with its e¡ect on vascular per-
meability. These ¢ndings suggest that the angiostatin-induced
reduction in vascular permeability may be ascribed, at least in
part, to its downregulation of VEGF expression.
Recently, we have shown that the BRB is compromised in
OIR rats [17]. Therefore, we tested the e¡ect of angiostatin on
vascular permeability using both the OIR as well as STZ
diabetes models. It has been shown that angiostatin-induced
inhibition of neovascularization in the OIR model occurs rel-
ative late (P21) [4]. In contrast, the angiostatin-induced reduc-
tion of retinal vascular permeability in the same model can be
detected as early as 1 day after the injection (Fig. 2). Analysis
of retinal vasculature showed that angiostatin injection (7.5
Wg/eye) did not result in any signi¢cant decrease of retinal
neovascularization in the OIR model. To further con¢rm
these ¢ndings, we also determined the e¡ect of angiostatin
on vascular permeability in STZ-induced diabetic rats which
lack retinal neovascularization while showing a signi¢cant in-
crease in vascular permeability [18]. Angiostatin also sig-
ni¢cantly reduced vascular permeability in this STZ-diabetic
animal model. Taken together, these results suggest that
angiostatin-induced reduction in vascular permeability is not
through its inhibition of neovascularization.
Although retinal edema in diabetes is a complex disorder,
several lines of evidence suggest that VEGF plays a key role
in vascular leakage in diabetic retina [19^22]. In OIR and STZ
diabetes models, retinal vascular leakage may be due to di¡er-
ent structural changes in retinal capillaries. However, both the
models have increased VEGF levels in the retina, which is
believed to play a key role in the development of vascular
abnormalities in the retina [10,22]. VEGF is also known as
a vasopermeability factor [22^24] and is 50 000 times more
potent than histamine in increasing dermal microvascular per-
meability [25]. Overexpression of VEGF is associated with
vascular leakage in diabetes [26]. Angiostatin blocks the over-
expression of VEGF in the hypoxic retina as found in OIR
and STZ diabetes but does not decrease the VEGF level in the
normal retina (Fig. 4). Correlating with this observation, an-
giostatin only reduces retinal vascular permeability in OIR
and STZ-diabetic rats but not in normal rats.
Another evidence supporting that the angiostatin-induced
reduction in vascular leakage is via blockade of VEGF pro-
duction is that angiostatin did not reduce vascular hyperper-
meability induced by an intravitreal injection of exogenous
VEGF (data not shown). Taken together, these results suggest
that the blockade of VEGF expression in hypoxic retina is
responsible, at least in part, for the angiostatin-induced reduc-
tion of vascular leakage in OIR and STZ-diabetic rats.
It is unclear how angiostatin blocks VEGF expression at
Fig. 5. Immunohistochemistry of VEGF. Rats with OIR received an
intravitreal injection of 7.5 Wg/eye angiostatin in the right eye and
PBS in the left eye at age P14. The eye was enucleated at P15 and
retinal sections labeled with an anti-VEGF antibody using the ABC
method. VEGF signal is in brown color. A: Retina from the OIR
rat with PBS injection stained in the absence of the anti-VEGF
antibody for negative control. B: Retina from the OIR rat after
PBS injection. C: Retina from the OIR rat after angiostatin injec-
tion. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, out-
er nuclear layer; RPE, retinal pigment epithelium.
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the present time. However, it has been shown that angiostatin
binds to integrins [27] and inhibits the activation of the p42/
p44 mitogen-activated protein (MAP) kinase pathway [28]. As
evidence has shown that the p42/p44 MAP kinase pathway
plays a role in the regulation of VEGF expression and in
angiogenesis control [29,30], the angiostatin-induced blockade
of VEGF expression may be through the inhibition of MAP
kinase pathway under hypoxia.
The BRB breakdown or vascular leakage is a major cause
of macular edema in diabetic retinopathy and other ocular
diseases such as uvietis [31^33]. Current therapies for diabetic
macular edema are not satisfactory, and macular edema is still
a major cause of vision loss in diabetic patients. The present
study demonstrates that angiostatin can reduce vascular leak-
age in both diabetic and OIR rat models. Angiostatin down-
regulates VEGF expression and thus blocks the major cause
of vascular leakage in diabetic retinas. Therefore, the angio-
statin-induced reduction of vascular leakage may have thera-
peutic potential in the treatment of diabetic macular edema,
cystoid macular edema and other diseases with vascular leak-
age such as uvietis and the wet form of macular degeneration.
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